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whether this signiﬁcant relation is still present after
receiving treatment. If this relation is absent potential
mechanisms (e.g. coping style) that could explain dis-
crepancies will be investigated.
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SYMPTOMATIC GASTRO OESOPHAGEAL
REFLUX DISEASE
Hughes DA1, Dubois D2
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OBJECTIVES: To model the 1-year cost-utility of
rabeprazole and esomeprazole “on demand” (prn) treat-
ment for symptomatic gastro oesophageal reﬂux disease
from the perspective of the UK National Health Service.
METHODS: Data relating to treatment discontinuation
due to inadequate heartburn control were extracted from
two clinical trials; one comparing rabeprazole 10mg with
placebo prn and the other comparing esomeprazole 
20mg, 40mg and placebo prn. Survival data (proportion
of patients continuing therapy) were ﬁtted to Weibull
functions, and adjusted for comparability according to
placebo data. Data from the trials on drug intake, use of
antacids as rescue medication and severity of heartburn
symptoms were also used for the analysis. Health care
resource utilization included annual frequency of general
practitioner and gastroenterologist consultation and of
upper GI endoscopy, annual number of drug prescriptions
and pharmacy dispensing fees. These were priced accord-
ing to the latest NHS costs. Health state utilities were
derived from a study that assessed EQ-5D utilities in 1003
patients with GERD, and related utility scores to dura-
tion and severity of symptoms. A probabilistic model was
employed that sampled from Weibull distributions for
survival time, assigned Poisson distributions to annual
frequency of events, Beta distributions to utilities and
Dirichlet distribution to severity of heartburn. RESULTS:
The mean total costs of therapy with rabeprazole 10mg,
esomeprazole 20mg and 40mg were £93, £103, and
£121, respectively. The associated utility scores were,
respectively, 0.866, 0.861 and 0.860. CONCLUSIONS:
For non-erosive reﬂux oesophagitis, treatment with
rabeprazole 10mgprn is less expensive than with either
20mg or 40mg esomeprazole prn. All three alternatives
are comparable in terms of their effectiveness.
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OBJECTIVES: To compare the costs and consequences 
of Enteryx with Laparascopic Nissen Fundoplication
(LNF) and pharmacological therapy (PPIs) in patients
with Gastro-Oesophageal Reﬂux Disease (GORD). The
Enteryx Procedure is a new endoscopically injected
polymer-based treatment for GORD. METHODS: A
decision analytical approach was taken to model the
ability of the three interventions to successfully treat
patients with GORD. The model time horizon was one
year with an additional 5-year long-term perspective. The
clinical outcomes and the resource consumption data 
for PPIs were derived from the literature. A multicentre
clinical study of Enteryx provided the clinical outcomes
for Enteryx. Treatment outcomes following LNF were
sourced from the literature. Experienced UK experts pro-
vided resource consumption data for the Enteryx proce-
dure and LNF. Patients on pharmacological treatment
(PPIs) with relapse followed the recommended route of
moving to higher dose therapy for eight weeks and if still
not responding received a further eight weeks followed
by an endoscopy. RESULTS: At 1-year average costs per
patient were lower with Enteryx (£2683) than with LNF
(£4718). The cost of PPI treatment at 1 year amounted
to £394 for all patients and to £691 for patients needing
a higher dose of treatment. At 5 years, Enteryx patients
had a lower cost of £3004 per patient compared to LNF
(£4769) and high dose PPI users (£3457). The average
cost for all PPI users at 5 years was £1970. CONCLU-
SIONS: For those patients suitable for surgery, Enteryx
provides a less expensive option than LNF largely due to
the reduced hospitalisation and procedure costs. Due to
the recurrent nature of PPI treatment and cost, Enteryx
is a cost saving therapy in the long-term compared to
pharmacological therapy, especially for patients on high
maintenance dose.
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OBJECTIVES: To estimate the cost of illness and the
disease burden, in terms of disability adjusted life years
(DALYs), for gastroenteritis in the Netherlands in 1999.
METHODS: The study population consisted of a com-
munity-based prospective cohort study on gastroenteritis,
with a nested case-control study, in cooperation with the
Dutch sentinel general practice network. Cases with gas-
troenteritis identiﬁed in the cohorts were requested to
submit stool samples, complete a questionnaire on risk
factors and complete a medical diary for four weeks. In
this diary, cases reported daily about symptoms, absence
from work or school, use of medication and use of health
services, such as GP and hospital services. Health services
use and productivity losses were valued according to
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Dutch guidelines for pharmacoeconomic research.
DALYs were calculated using data on number of deaths
due to gastroenteritis and age at death from Statistics
Netherlands. Disability weights for both mild and severe
cases of gastroenteritis were taken from a Dutch national
study on the burden of diseases. RESULTS: Of the 4860
participants in the cohort, 1052 case episodes were
observed. Of these cases, 774 (74%) participated in the
case-control component. Of these, 646 (83%) completed
data collection. The overall standardised incidence of 
gastroenteritis was 283 per 1000 person-years, with an
estimated total of 4.5 million cases per year. Total costs
per case were €68.80, with productivity losses (€55.50)
being the major cost driver. Total cost to society were esti-
mated at €308 million in 1999 (95% CI €221–393
million). Gastroenteritis was associated with a loss of
67,000 DALYs. CONCLUSIONS: Although costs and
disease burden are low for individual cases, gastroenteri-
tis is associated with a high disease burden and con-
siderable costs to society due to a high incidence in the
population.
GD4
POTENTIAL HOSPITAL SAVINGS RELATED TO
THE ADMINISTRATION OF ESOMEPRAZOLE
TABLETS THROUGH GASTRIC TUBES IN
PATIENTS CURRENTLY TREATED WITH
INJECTABLE PPIS
Duru G1, Bernard-Chabert B2, Begue D3, Longin J4,
Barthelemy P5, Lamarque H5
1Université Lyon 1, Lyon, France; 2C.H.U Reims, Reims, France;
3Université de Pharmacie Paris V, Paris, France; 4NAXIS, Lyon,
France; 5Laboratoire AstraZeneca, Rueil Malmaison, France
OBJECTIVES: Intravenous Proton Pump Inhibitors
(PPIs) are widely used in hospital. The galenic formula-
tion of esomeprazole tablets (Multi Unit Pellet System)
enables water dispersion and subsequent administration
through a gastric tube (GT), thus offering an alternative
to injectable PPIs. The primary objective of this study was
to estimate the percentage of hospital patients treated
with intravenous PPIs that are potential candidates to a
treatment with esomeprazole tablets administered via a
GT. Secondary objectives were to derive the subsequent
savings in terms of drug acquisition cost and nurses time
saving. METHODS: Hospitals, stratiﬁed on their admin-
istrative status, were randomly selected. In each hospital,
departments consuming more than 80% of the total
injectable PPIs were identiﬁed. Patient data collection
(including presence of a GT) was done during one single
day. The time to administrate injectable PPI and
esomeprazole tablets through a GT was estimated by
nurses; drug cost calculations were done with undis-
counted prices including taxes. RESULTS: A database
including 179 patients in 19 different hospital centres was
collected. Mean age (SD) was 61.9 (16.3) years and
53.9% of patients were male. Patients were hospitalised
for 13.1 (16.5) days in surgery department (41%),
medical department (37.1%), intensive care unit (21.9%).
A total of 46.6% of patients were hospitalised for cancers
and 30.1% for digestive diseases. Total number of
patients which had GT was 33.3%. Median nurse times
to administrate injectable PPI and esomeprazole tablets
through a GT were respectively 5 and 3 minutes (-40%),
while the drug costs were respectively €8.08 and €1.49 
(-82%). CONCLUSIONS: This study shows that 33%
of patients treated with injectable PPI have a gastric tube.
These patients are potential candidates to be treated with
esomeprazole tablet through a gastric tube with signiﬁ-
cant beneﬁts both in terms of drug acquisition cost and
nurse time saving.
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The PROGRESS trial demonstrated the effectiveness of
perindopril/indapamide in secondary stroke prevention
(SSP). No existing economic study has incorporated these
ﬁndings in a cost-beneﬁt analysis. OBJECTIVES: The
objective of this analysis was to evaluate the cost/beneﬁt
of perindopril/indapamide in SSP. METHODS: The
model used a decision tree approach to estimate direct
cost savings associated with SSP for a hypothetical cohort
of 10,000 ﬁrst stroke survivors from an HMO’s perspec-
tive (1 Mio covered lives) over a 3-year time period. Inci-
dence estimates for 2nd stroke and Health care utilization
as well as pharmacoeconomic estimates are presented 
for each year and separated for the two major stroke
types (ischaemic and hemorrhagic stroke). First, stroke
incidence and transition probabilities for Health care 
utilization were ed from the published epidemiologic 
literature, incidence of second strokes from the
PROGRESS trial. Cost for stroke-related hospitalization
and re-hospitalization, rehabilitation, nursing home, and
ambulatory care derived from national data and pub-
lished literature. Historical cost data was inﬂation-
adjusted to 2001 values, savings in the 2nd and 3rd year
were discounted at 3%, and health care CPI inﬂation-
adjusted at 4.7%. Treatment and control group (no SSP
medication) were replenished after the 1st and 2nd year
in equal numbers with newly SSP eligible patients (new
ﬁrst stroke survivors of the HMO population). Drug
prices were deﬁned as WAC-20% plus $5 co-pay. Sensi-
tivity analysis on stroke incidences, selected transition
probabilities and costs will be presented. RESULTS: SSP
with perindopril/indapamide saved 28 lives and 110
strokes in the ﬁrst year (after 3 years 169 and 325 respec-
tively). Treatment achieved a net beneﬁt of $803,000 in
the ﬁrst, $3,267,253 in the second and $6,207,814 by the
third year. The cost per stroke prevented was $24,648 and
$47,412 per death averted over the 3 year period. 
